Stock Financial Ratios, Dividends, Split History
QSR / Restaurant Brands International Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.
|Market Cap ($M)||15,719.60|
|Enterprise Value ($M)||29,177.07|
|Book Value ($M)||2,078.00|
|Book Value / Share||8.34|
|Price / Book||7.56|
|NCAV / Share||-60.34|
|Price / NCAV||-1.06|
|Weighted Average Number Of Shares Outstanding Basic||237,000,000|
|Weighted Average Number Of Diluted Shares Outstanding||477,400,000|
|Common Stock Shares Outstanding||243,899,476|
|Common Shares Outstanding||243,935,852|
|Altman Z Score||N/A|
|Beneish M Score||N/A|
|Management Effectiveness (mra)|
|Return on Invested Capital (ROIC)||0.09|
|Return on Assets (ROA)||0.06|
|Return on Equity (ROE)||0.73|
|Income Statement (mra) ($M)|
|Franchise Fees And Other Revenue||205,600,000.00|
|Franchise And Property Revenues||2,185,800,000.00|
|Sales Revenue Goods Net||2,390,300,000.00|
|Earnings Per Share Basic||2.64|
|Earnings Per Share Diluted||2.54|
|Cash Flow Statement (mra) ($M)|
|Cash From Operations||1,382.00|
|Cash from Investing||-857.80|
|Cash from Financing||-857.80|
|Identifiers and Descriptors|
|Central Index Key (CIK)||1618756|
|76131D903 076131D10 76131D953|
|SIC 5812 - Restaurants, Dining, and Eating Places|
Stock splits are used by Restaurant Brands International Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.
2018-07-13 - Asif
Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...
2018-07-09 - Asif
Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...
2018-07-06 - Asif
Overview Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company's proprietary paresthesia-free HF10TM therapy, delivered by its Senza system, was demonstrated in its SENZA-RCT study to be superior to traditional SCS therapy with it being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. Comparatively, traditional SCS therapy has limited efficacy in treating back pain and is used primarily for treating leg pain, limiting its market adoption. The company's SENZA-RCT study, along with its European studies, represents what the company believe is the most robust body of clinical evidence for any SCS therapy. The compa...
Related News Stories
Chicago, IL – July 13, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Lululemon Athletica Inc. (LULU - Free Report) , Bank of Montreal (BMO - Free Report) , The Toronto-Dominion Bank (TD - Free Report) , Sun Life Financial Inc. (20-1)
We reiterate our highest rating (3) on news that John Schnatter has resigned as Chairman of the Board.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (4-0)
The Canadian economy showed resilience to harsh winters and global economic crisis and exhibited growth in April. Economists had largely written off growth for the period. However, in its latest report released on Jun 29, an unexpected spurt in Canada’s growth has increased the likelihood of a rate hike by the Bank of Canada in July. (8-0)
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com (4-1)
as of ET